Yu Kato
7Patents
2h-index
18Co-inventors
40Inventor score
Filing activity: Mar 3, 2016 → Jan 6, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11547705B2 | Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer | Chemistry; Metallurgy | 3 | Active |
| US9527921B2 | Anti human Notch4 antibody | Chemistry; Metallurgy | 2 | Active |
| US9969812B2 | Anti human Notch4 antibody | Chemistry; Metallurgy | 1 | Active |
| US12246097B2 | Nanoparticle vaccine adjuvant and methods of use thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US11147806B2 | Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer | General | 0 | Revoked |
| US11547672B2 | Nanoparticle vaccine adjuvant and methods of use thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US12083112B2 | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.